Clinical Trials

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06717347 2026-04-16

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06172296 2026-04-14

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

478 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT06422806 2026-04-14

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

365 enrolled

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT05675410 2026-04-13

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06191744 2026-04-13

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06966700 2026-04-13

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07044336 2026-04-13

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

700 enrolled

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT07441460 2026-04-08

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

1,800 enrolled

Resectable HER2-positive Breast Cancer

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

LymphoidOther hematologic neoplasm

5,951 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT06340568 2026-03-31

Fern-EC-01

480 enrolled

Endometrial Neoplasms

NCT04685616 2026-03-30

RADAR

1,042 enrolled

Hodgkin Disease

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06088290 2026-03-11

SaLuDo

450 enrolled

Leiomyosarcoma, Neoplasms

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06401330 2026-03-05

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

1,656 enrolled

Genitourinary

Stage I Mixed Cell Type Kidney Wilms Tumor

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

750 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT06647953 2026-02-24

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

110 enrolled

Pleuropulmonary blastoma

NCT06220032 2026-01-05

HO170DLBCL

324 enrolled

LymphoidSarcoma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

NCT06006117 2025-12-19

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

260 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT06855069 2025-12-17

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

468 enrolled

Ovarian Neoplasms

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT05929768 2025-11-05

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

2,400 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT06072131 2025-10-23

CRESCENDO

504 enrolled

Lymphoma, T-Cell, Peripheral

NCT03805022 2025-10-02

CIRSARC

351 enrolled

NCT06947967 2025-09-15

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

224 enrolled

Lymphoma, T-Cell, Peripheral

NCT04478292 2025-05-18

A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy

330 enrolled

Gastrointestinal

Hepatoblastoma

NCT03643276 2025-04-06

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

LymphoidOther hematologic neoplasm

5,000 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04757337 2025-03-25

GERICO14

214 enrolled

NCT04043494 2025-03-21

LBL 2018

LymphoidOther hematologic neoplasm

683 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06584032 2025-01-07

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

412 enrolled

Endometrial Neoplasms

NCT06284122 2024-10-15

MorningLyte

790 enrolled

Lymphoma, Follicular

NCT04638790 2024-09-27

HL-Russia-1

300 enrolled

Hodgkin Disease

NCT06394492 2024-08-09

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

440 enrolled

Ovarian Neoplasms

NCT04650984 2024-04-08

FIBROSARC

102 enrolled

NCT05351346 2023-03-24

Genotype-guided Treatment in DLBCL

1,100 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01704716 2020-10-23

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)